QT Imaging utilizes transmission and reflection ultrasound to generate highly detailed images of the human anatomy. The QTscan® is FDA-cleared for breast imaging and the company hopes that the technology platform may one day offer whole body applications including orthopedics and infant imaging.
We are pleased to share with you many of the exciting things our research team is working on. The products and technology described in this section are not FDA-cleared and not commercially available, at this time.
QBD is the innovative new technology that promises to measure breast density, with no radiation or compression. This feature is only available in QT Imaging’s Research Mode and is not FDA cleared.
Steps in the quantitative breast density algorithm: Top row, speed of sound images. Middle row, breast separated from the water bath with skin and fibroglandular tissue segmented from the total breast tissue volume. Bottom row, remaining fibroglandular tissue following the segmentation and removal of skin.
QT Imaging’s research shows that it has the potential to measure and follow masses in the breast with high accuracy and precision. Our technology generates 3D speed-of-sound maps that can be used to perform volumetric measurement. Tumor volume doubling time is associated with growth rate and tumor biology. We hope to one day be able to provide the accurate measurement of tumor volume which is critical for oncologic diagnosis, staging, and treatment, including quantification of neoadjuvant response.
Bland-Altman plots showing absolute agreement between volume of mass assessed using (left) ground truth and QT, (middle) ground truth and HHUS-spherical method, and (right) ground truth and HHUS-ellipsoid method. The spherical and ellipsoid methods corresponding to volume calculation formulas.
QT Imaging’s research and development includes what may soon be the first artificial intelligence-enabled algorithm in transmission ultrasound to aid in the diagnosis of cancer. AI-based algorithms have gained tremendous acceptance throughout medical imaging and we hope to provide radiologists with a tool that can increase specificity. AI tools with the QTviewer® may enable features analysis to categorize findings as either benign or malignant. Our goal is to markedly reduce false positives and unnecessary biopsies. This is not an FDA cleared feature.
The QTscan is FDA cleared for breast imaging and is a true 3D transmission ultrasound technology without harmful radiation or painful compression. The technology produces high-fidelity detailed scans, providing clarity even for women with dense breasts.
Looking forward, this new imaging modality has the potential for additional clinical benefits as transmission ultrasound has imaged microanatomy in living humans and has identified human tissue types using speed of sound, as part of QT Imaging’s research. QT delivered the first ever 3D printing of human breast tissue-specific microanatomy using any medical imaging modality and has the potential to be a new diagnostic tool, and a new way for physicians to visualize human health and disease.
Transmission ultrasound offers the potential to be a new diagnostic imaging modality, for the whole body, including the most difficult regions. Even in the presence of bone, the technology may provide: